CVAC Stock Overview
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.83 |
| 52 Week High | US$10.96 |
| 52 Week Low | US$2.10 |
| Beta | 2.5 |
| 1 Month Change | 0.36% |
| 3 Month Change | -15.39% |
| 1 Year Change | -63.63% |
| 3 Year Change | -96.65% |
| 5 Year Change | n/a |
| Change since IPO | -93.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVAC | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 23.4% | 2.7% | 1.0% |
| 1Y | -63.6% | -10.7% | 4.6% |
Return vs Industry: CVAC underperformed the Austrian Biotechs industry which returned -10.7% over the past year.
Return vs Market: CVAC underperformed the Austrian Market which returned 4.6% over the past year.
Price Volatility
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.1% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: CVAC's share price has been volatile over the past 3 months.
Volatility Over Time: CVAC's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,086 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. Fundamentals Summary
| CVAC fundamental statistics | |
|---|---|
| Market cap | €650.89m |
| Earnings (TTM) | -€260.17m |
| Revenue (TTM) | €53.76m |
12.1x
P/S Ratio-2.5x
P/E RatioIs CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAC income statement (TTM) | |
|---|---|
| Revenue | €53.76m |
| Cost of Revenue | €116.21m |
| Gross Profit | -€62.45m |
| Other Expenses | €197.71m |
| Earnings | -€260.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -116.17% |
| Net Profit Margin | -483.96% |
| Debt/Equity Ratio | 0% |
How did CVAC perform over the long term?
See historical performance and comparison